In pediatric thyroid carcinomas, RET/PTC fusions are more commonly observed (ranging from 37% to 87%), while BRAF and RAS mutations are rarely detected (0–16% and 0–6%, respectively) [6,9,10,11]. This evidence concerns the gene RET and thyroid gland carcinoma.